Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Headache|October 4, 2024
Characterization of rimegepant drug-drug interactions using the cytochrome P450 probe drugs, itraconazole, rifampin, fluconazole, and midazolamRajinder Bhardwaj, Beth Morris, Kyle T Matschke, et al.
Therapeutic Advances in Drug Safety|February 13, 2019
Effects of intravenous oxycodone alone or in combination with naltrexone on measures of respiratory depression: a randomized placebo-controlled studyAlmasa Bass, Lynn R Webster, Kyle T Matschke, et al.
European Journal of Drug Metabolism and Pharmacokinetics|June 29, 2026
A Relative Bioavailability Study of Vepdegestrant Tablets in Healthy Adult ParticipantsDerek Z Yang, Kyle T Matschke, Jennifer A Kimberly C WintonLee, et al.
Clinical Pharmacology in Drug Development|November 22, 2025
A Phase 1, Randomized, Placebo-Controlled, Multiple-Dose, Double-Blind Study to Evaluate and Compare the Pharmacokinetics and Safety of Rimegepant in Healthy Adult Japanese and Caucasian IndividualsRajinder Bhardwaj, Chay Ngee Lim, Yinhua Li, et al.
Headache|November 7, 2024
Comparative bioavailability of single-dose zavegepant during and between migraine attacks: A phase 1, randomized, open-label, fixed-sequence, two-period studyRichard J Bertz, Julie L Collins, Jennifer Madonia, et al.
Clinical Therapeutics|January 20, 2026
The Effect of Itraconazole on the Pharmacokinetics of Vepdegestrant, a PROteolysis TArgeting Chimera Estrogen Receptor Degrader, in Healthy Adult ParticipantsLana Tran, Jennifer A Winton, Kyle T Matschke, et al.
Clinical and Translational Science|March 5, 2024
No clinically relevant electrocardiogram effects in a randomized TQT study of single therapeutic/supratherapeutic rimegepant doses in healthy adultsRajinder Bhardwaj, Michael S Hanna, Beth A Morris, et al.
Headache|August 27, 2025
Safety, tolerability, and pharmacokinetics of single and multiple ascending doses of zavegepant nasal spray in healthy adults from two phase 1 randomized, placebo-controlled trialsRichard Bertz, Mary Donohue, Jennifer Madonia, et al.
Cephalalgia : an International Journal of Headache|February 17, 2024
Bioequivalence of rimegepant, a small molecule CGRP receptor antagonist, administered as an oral tablet, a sublingual orally disintegrating tablet, and a supralingual orally disintegrating tablet: two phase 1 randomized studies in healthy adultsRobert Croop, Rajinder Bhardwaj, Matt S Anderson, et al.
British Journal of Clinical Pharmacology|February 18, 2026
Effect of carbamazepine on the pharmacokinetics of vepdegestrant, a PROteolysis TArgeting Chimera estrogen receptor degrader, in healthy adultsHechuan Wang, Jennifer A Winton, Kyle T Matschke, et al.
Pageof 2